Pharmaceutical Composition Comprising Udenafil
Patent No. EP4005556 (titled "Pharmaceutical Composition Comprising Udenafil") was filed by Corepharm BIO on Jul 24, 2020. The application was issued on Feb 19, 2025.
Patent Summary
A pharmaceutical composition containing udenafil, a phosphodiesterase type 5 inhibitor, in a liquid or syrup formulation for oral administration. The composition includes udenafil, a pH adjusting agent, and cyclodextrin or a derivative thereof, and has a viscosity of 0.4 Pa·s to 4 Pa·s and a pH ranging from 3 to 6. The cyclodextrin derivative is selected from a group including α-cyclodextrin, β-cyclodextrin, and their derivatives. The composition is suitable for treating erectile dysfunction and Fontan disease in infants and children.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4005556
- Application Number
- EP20848224A
- Filing Date
- Jul 24, 2020
- Status
- Granted And Under Opposition
- Jan 17, 2025
- Publication Date
- Feb 19, 2025
- External Links
- Slate, Register , Google Patents